Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors
Abstract Background The utilization of modern-immunotherapies, notably immune checkpoint inhibitors (ICIs), has increased markedly in patients with metastatic melanoma over the past decade and are recommended as standard treatment. Given their increasing adoption in routine care for melanoma, unders...
| الحاوية / القاعدة: | BMC Cancer |
|---|---|
| المؤلفون الرئيسيون: | , , , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
BMC
2023-07-01
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s12885-023-11142-4 |